Patented silver chloride and chitosan therapeutic serum for chronic inflammatory skin conditions
A patented topical therapy combining silver chloride and chitosan for chronic inflammatory skin conditions including psoriasis, eczema, acne, hidradenitis suppurativa, burns, and diabetic wounds. Reduces inflammation, eliminates harmful bacteria, promotes healing, and forms a protective film against free radicals. Proven non-toxic with 60+ efficacy studies and 8 years of European market use.
Overview
This patented therapeutic serum combines silver chloride and chitosan to address chronic inflammatory skin conditions including psoriasis, eczema, acne, hidradenitis suppurativa, burns, and hard-to-heal diabetic wounds. The formulation reduces inflammation, eliminates harmful bacteria while maintaining a healthy skin staph profile, and promotes healing by encouraging the production of beneficial growth factors. It also forms a thin protective film on the skin surface to shield against free radical absorption and oxidation.
The product has been sold as a beauty item in Europe for over eight years, accumulating thousands of four-star consumer reviews. The company holds new intellectual property covering manufacturing processes and therapeutic uses, including potential application as an inhaled drug therapy for lung diseases. Because the serum can be used continuously over long periods to maintain its anti-inflammatory effects, it supports a recurring revenue model for chronic condition management.
Technical specifications
Key features and benefits:
- Reduces inflammation and supports proper skin staph profile
- Kills harmful bacteria on skin and inhibits cross-adaptation of bacteria
- Eradicates biofilms safely
- Promotes production of beneficial growth factors to aid healing
- Forms a thin protective film against free radicals and oxidation
- Proven non-toxic on dermis with no inhalation, oral, or ocular risk
- No cytotoxicity observed
- Manufacturable with ultra-pure U.S.P. registered chitosan, including mushroom chitosan for vegan claims
- EPA/FDA toxicity and sensitization testing passed as Category IV minimal risk
- Over 60 efficacy studies completed against a wide range of bacteria and fungi
Validated applications:
- Topical therapy for psoriasis, eczema, acne, hidradenitis suppurativa, burns, and diabetic wounds
- Potential inhaled therapy for lung diseases including Pseudomonas aeruginosa infections in cystic fibrosis patients
- Possible OTC remedy to shorten flu and viral infections
- Suggested treatment for tuberculosis and demonstrated effectiveness against Candida Auris and SARS-CoV-2
Technology readiness level
The technology has undergone extensive external research at university laboratories in the United States, United Kingdom, and Australia. The Australian Institute of Microbiology and Infection has validated the inhibition of cross-adaptation. Ingredients are FDA GRAS, listed on the OTC monograph, and included on the EPA Safer Choice ingredient list. The company is planning to advance to clinical trials and has obtained quotes from two clinical study firms. Researchers at the Australian Institute of Microbiology and Infection have an extensive research plan for inhaled therapy applications. The product has a commercial track record of over eight years in the European beauty market, providing real-world consumer validation.
About Chitozan Health LLC
Chitozan Health LLC is a biotechnology research firm that develops antimicrobial solutions utilizing patented silver-chitosan technology [1][3][5]. Their core innovation, marketed as Silver Shell or Glucosil, incorporates chitosan and silver particles to create durable, effective antimicrobial barriers for various applications [1][5][8]. By leveraging the biostatic properties of chitosan, the company produces textile finishes and topical gels that are designed to combat pathogens, including bacteria, fungi, and viruses, while minimizing the use of silver and maintaining safety standards [1][5][8]. This research is supported by NIH NIAID funding and focuses on managing infections, such as those related to Pseudomonas aeruginosa in cystic fibrosis, as well as providing broad-spectrum protection in healthcare and consumer settings [1][5][7].
These products serve a range of stakeholders, from industrial partners in textile manufacturing and sustainable packaging to healthcare providers and individual consumers in need of advanced wound and burn care [1][4][7][8]. The company's technology addresses critical challenges such as antimicrobial resistance, infection control, and the environmental impact of synthetic materials [1][4][8]. Through rigorous independent laboratory testing, their treatments have demonstrated significant efficacy in reducing pathogen populations and sustaining performance even after multiple commercial wash cycles [1][5]. With a focus on sustainable, naturally derived materials, Chitozan Health aims to provide safer, more effective alternatives for infection mitigation across multiple sectors [1][7].
delivered to your inbox.